ABSTRACT Degradation of bradykinin (BK) in human plasma was investigated by searching for a stable metabolite as a marker of kinin release in vivo. BK, incubated with diluted plasma, was de graded to des-Arg9-BK (des-9-BK), des-Phe8-Arg`'-BK (des-8,9-BK) and Arg-Pro-Pro-Gly-Phe ([1 5]BK). Des-9-13K was degraded to [1] [2] [3] [4] [5] BK without an increase in des-8,9-BK, and des-8,9-BK was also degraded to [1] [2] [3] [4] [5] BK. D,L-2-Mercaptomethyl-3-guanidinoethyl-thiopropanoic acid inhibited the forma tion of des-9-BK from BK, whereas captopril inhibited the formation of des-8,9-BK from BK as well as that of [1] [2] [3] [4] [5] BK from des-9-BK or des-8,9-BK. The half lives of BK, des-9-BK, des-8,9-BK and [1-5]BK under the present experimental conditions were 60 min, 90 min, 14 min and 4.2 hr, respectively. Among the metabolites, [1-5]BK was the most stable one and may be used as a marker for BK production in vivo.
Bradykinin (BK) is a very potent proinflammatory peptide that induces vasodilatation, increased vascular permeability, pain, and decreased blood pressure. However, this active peptide is quickly degraded by peptidases in the plasma and other biological fluids and by those released from a variety of cells, so that the half-life of bradykinin in plasma is reported to be approximately 17 sec (1, 2) . Thus, it is extremely diffi cult to detect it in biological fluids. Major peptidases in the plasma are kininase I and kininase 11 (3, 4) , which are carboxypeptidase N and a dipeptidyl peptidase analo gous to angiotensin converting enzyme, respectively (5) . The difficulty in the detection of bradykinin has hampered verification of the involvement of the kallikrein-kinin system in pathological states. Thus, de tection of the degradation products in such states may be one way to verify the kinin release. Des-Phe8-Arg9 bradykinin (des-8,9-BK) is a product of degradation by kininase II, and we have proved that des-8,9-BK can be an excellent and more stable marker of the formation of BK in the pleural exudates in carrageenin-induced pleurisy in rats (6, 7) . The degradation pathway has been explored (8 12) , and a tripeptide, Arg-Pro-Pro, is reported to be a final stable peptide in that degrada tion (12) .
The present experiment is aimed at clarification of the degradation pathway of bradykinin in human plas ma to obtain a better parameter for the involvement of the kallikrein-kinin system in vivo and to report that the tetrapeptide Arg-Pro-Pro-Gly-Phe is a stable de gradation product in plasma.
MATERIALS AND METHODS

Blood collection
Venous blood was collected in plastic tubes contain ing 1/10 of its volume of 3.8% sodium citrate, from the cubital veins of healthy male volunteers years of age) who had not taken any medication, in cluding aspirin, for a week. Citrated blood was im mediately centrifuged at 1500 X g for 15 min (25°C), and the plasma was obtained. Plasmas collected were pooled, distributed into plastic tubes and frozen at -80°C until use . Five sets of plasmas collected from 5 15 volunteers on different days were frozen. Protein concentrations of the pooled plasmas were 74.0 ± 1.7 (n = 5).
Incubation of peptides with plasma
Human citrated plasma (100,ul), physiological saline (200 ,u l) and a solution of appropriate inhibitors or saline (50,ul) were added to 10-ml glass tubes sili conized with trimethyl chlorosilane. After preincuba tion for 10 min at 37°C, the mixtures were incubated for the given periods at 37°C with 40 nmol/100 ,ul of one of the following peptides: BK; des-Arg9-BK (des 9-BK); des-Phe8-Arg9-BK (des-8,9-BK); a penta peptide, Arg-Pro-Pro-Gly-Phe ([1-5]BK); and a tri peptide, Arg-Pro-Pro ([1-3]BK). The reaction was stopped by addition of the appropriate amount of 20% trichloroacetic acid (TCA, 450,u1) so that the final con centration of TCA was 10%. The mixture was centri fuged at 1,500 X g, at 4°C for 15 min, and the super natant (600 ul) was transferred to other siliconized tubes, which were then washed three times with 2 ml of diethyl ether to remove TCA. The solution was dried at reduced pressure and kept at -20°C. Im mediately before HPLC analysis, the residue was dis solved in saline (150 ul). Separation by high performance liquid chromatography (HPLC) The sample solution (45 u l) was applied to the col umn (RPC-SC18, 4.6 mm (inner diameter) X 250 mm, a mean particle diameter of 7 ,um, Japan Spectroscopic Co., Ltd., Tokyo, Japan), using a pump (Trirotor-III, Japan Spectroscopic Co., Ltd., Tokyo, Japan) at the speed of 1 ml/min. The peptides were detected by an UV detector (UV DEC100-IV, Japan Spectroscopic Co., Ltd., Tokyo) at a wave length of 210 nm. Fig. 1 shows, the retention times for the in dividual peptides were 24 min for [1] [2] [3] [4] [5] BK, 26 min for des-8,9-BK, 42 min for BK, 51 min for des-9-BK and 16 min for the Arg-Pro-Pro fragment. Amino acids and small peptides were separated by HPLC under the same solution conditions as were used for Arg-Pro-Pro analysis. The retention times for Gly-Phe and Phe were 12 and 6.7 min under these conditions. The individual peptides were identified by co-elution with our own standard peptide and by amino acid analysis. The peptides were quantified by comparison with the peak height of standard peptides of known concentrations. The amino acid analysis was carried out with a PICO-TAGTM analyzer (Waters Associates, Milford, MA, USA).
Protein was determined by the Folin-Lowry method (Tokyo, Japan) and D,L-2-mercaptomethyl-3-guanidino ethyl-thiopropanoic acid (MGPA) was purchased from Calbiochem. Corp., La Jolla, CA, USA. Trimethyl chlorosilane, acetonitrile (AcCN), trifluoroacetic acid, isopropyl alcohol, trichloroacetic acid (TCA) and diethyl ether (Wako Pure Chemicals, Osaka, Japan) were used. Purified kininase II was purchased from Sigma Chemical Co., St. Louis, MO, USA.
Statistical analysis
Values were expressed as the mean ± S.E.M., and Student's t-test was used to evaluate the significance of difference. When variances were heterogeneous, statis tical analyses were performed by the Aspin-Welch method. 
RESULTS
Incubation of BK with plasma
Bradykinin (40 nmol) was incubated with human plasma (100 ,u l). Figure 2 shows the course of the de gradation of BK. One hour after the incubation began, the residual amount of BK was reduced to about 50%, and des-9-BK, des-8,9-BK and [1] [2] [3] [4] [5] BK could all be de tected. The major product was des-9-BK. At 3 hr, the amount of BK was overtaken by further increases in the amounts of these three peptides. After 5 hr of in cubation, the levels of des-9-BK and des-8,9-BK were decreased and overtaken by a further increase of [1 5 ]BK. The half-life of BK was approximately 60 min under the present experimental conditions (Fig. 2) . In crease in plasma volume from 100 to 300 ,u l did not differ the production ratios of the individual metabo lites, except for an increase in the production rates of the metabolites. The effect of inhibitors of the known kininases was evaluated at one hr after the start of incubation, when the BK level had fallen to approximately 50%. As shown in Table 1 , MGPA (10,uM), a kininase I inhibi tor, induced marked inhibition (P < 0.001) of des-9-BK formation without affecting the formation of des-8,9 BK and [1] [2] [3] [4] [5] BK. The degradation of BK was suppress ed by 53%. On the other hand, addition of captopril (30,uM), a kininase II inhibitor, induced significant in hibition of the formation of des-8,9-BK (P < 0.05) and [1] [2] [3] [4] [5] BK (P < 0.001) without effect on that of des-9 BK, resulting in only a 2% inhibition of BK degrada tion. The formation of des-8,9-BK and [1-5]BK was not further inhibited even by increasing the captopril doses to 3 mM (data not shown). The combination of the two inhibitors, MGPA and captopril, caused the same degree of suppression of des-9-BK (P < 0.001) and [1] [2] [3] [4] [5] BK (P < 0.001) formation, but that of des-8,9 BK (P < 0.05) was not further inhibited. Degradation of des-9-BK by human plasma When des-9-BK (40 nmol) was used as a substrate and incubated with human plasma (100,ul), the reduc tion of the residual amount of des-9-BK was accom panied with an increase in [1] [2] [3] [4] [5] BK (Fig. 3A) and Ser Pro-Phe (data not shown), but accumulation of des-8,9 BK could not be observed. The half-life of des-9-BK was approximately 90 min. As shown in Table 2 , this accumulation of [1] [2] [3] [4] [5] BK and the degradation of des-9 BK was markedly suppressed by captopril (30,uM), whereas MGPA (10,uM) inhibited the formation of [1] [2] [3] [4] [5] BK by 59% and the degradation of des-9-BK by 55%. The combination of both inhibitors suppressed the formation of these peptides almost completely. Purified kininase II, when preincubated with MGPA, was not inhibited in the degradation of des-9-BK (data not shown). This seems likely to indicate that the ma jor degradation pathway of des-9-BK is via the action of kininase II, and that minor pathways via the actions of kininase I and perhaps other proteases susceptible to MGPA also exist.
Degradation of des-8,9-BK by human plasma
The time course of degradation of des-8,9-BK (40 nmol) was examined during incubation with 100,ul of human plasma (Fig. 3B) . Des-8,9-13K was cleaved very rapidly as compared with BK or des-9-BK. The half life of des-8,9-BK was only 14 min. This rapid degrada tion was accompanied with the formation of [1] [2] [3] [4] [5] BK. Captopril (30,uM) blocked the degradation by 94% without a detectable amount of [1-5]BK (P < 0.01) ( Table 3 ). The combination of captopril and MGPA in duced a similar recovery rate of des-8,9-BK (94%), but MGPA (10,uM) itself induced slight inhibition of the formation of [1] [2] [3] [4] [5] BK (by 43%, P < 0.05), accom panied with partial inhibition of the degradation of des 8,9-BK by 56% (P < 0.05). The tripeptide Arg-Pro-Pro could not be detected in any experiments, with or with out inhibitors. The degradation of des-8,9-BK in plas ma was mainly due to kininase II, with supplementary degradation by kininase I or other kininases susceptible to MGPA. Degradation of [1] [2] [3] [4] [5] BK by human plasma The degradation process of [1] [2] [3] [4] [5] BK (40 nmol) by hu man plasma (100 ul) was further analyzed. Figure 4 shows chromatographs of the time course of the de gradation of [1] [2] [3] [4] [5] BK. At the 7th hr, the peak of [I 5113K was markedly reduced. The size of the peaks of Gly-Phe and Phe was increased (Fig. 4, A and B) . During the degradation of [1-5]BK, no peak for Arg Pro-Pro could be detected by the present method (Fig.  4, C and D) . Figure 5 summarizes the time course of the degradation of [1] [2] [3] [4] [5] BK. The half-life of the de gradation was 4.2 hr. MGPA (10,uM) , captopril (30 ,uM) and the combination of both inhibitors led to only slight inhibitions of both [1] [2] [3] [4] [5] BK degradation (15 24%) ( Table 4 , A) and the formations of Gly-Phe and Phe (data not shown). Thus, the degradation of [1 5 ]BK in the plasma may be due to peptidases other than kininases I and II.
Degradation of Arg-Pro-Pro with human plasma
The incubation of the tripeptide Arg-Pro-Pro (40 nmol) with human plasma (100 ,ul) resulted in its rapid degradation to smaller fragments or amino acids with a half-life of 46 min, which was a degradation rate twice as rapid as that of des-9-BK. During this degradation, the peaks of arginine and proline were increased, when analyzed by HPLC and with an amino acid analyzer (data not shown). The rapid degradation was slightly affected by MGPA (by 25%), but inhibited by capto pril (30 ,uM) by about 46% (Table 4B ). The combina tion of the inhibitors did not increase the inhibition rate. plasma. Kininase I was reported to be inhibited by MGPA (14) . Bradykinin is also degraded in plasma by kininase II, angiotensin converting enzyme, which is a peptidylpeptidase that cleaves His-Leu from the C-ter minus of angiotensin I to produce a potent vasopressor peptide, angiotensin II. This dipeptidyl peptidase also inactivates bradykinin by cleavage of Phe-Arg from its C-terminus (15) and is inhibited by captopril (16) . In the present in vitro experiments, bradykinin was initially degraded to des-9-BK and des-8,9-BK when it was incubated with human plasma. These initial de gradations were attributable to kininase I and kininase II, respectively. The activity of kininase I in human plasma was more potent than that of kininase II in this context, as shown by the time course of bradykinin de gradation (Fig. 1 ) and the inhibition experiment by MGPA ( Table 1) . The results described in the present paper agreed with the conclusion that des-9-BK was the predominant product after incubation of bradykinin with human serum (12) . Further, the conclusion of Sheikh and Kaplan (12) that des-9-BK was degraded by kininase II in serum, once all the bradykinin was converted to des-9-BK, was partly supported by the present experiment with human plasma. In the present experiments, degradation of des-8,9-BK was markedly inhibited by captopril (Table 2) , but des-8,9-BK appeared from the beginning in the incubation of BK with plasma ( Fig. 1) , and the amount of des-8,9-BK formed did not change in the presence of MGPA (Table 1 ). The reason for this difference is not known. The partial inhibition of the generation of des-8,9-BK by captopril could not exclude the possibility of the presence in human plasma of other peptidases such as post-proline-cleaving enzyme, which cleaves the pep tide bond of Pro'_Phe8 (17) . The present results with human plasma did not agree with our previous report, using plasma and inflammatory exudate from rats, that kininase II was predominant in the degradation of bradykinin (6) . This is due to the species difference.
In the present experiments, des-9-BK was degraded by human plasma to the pentapeptide Arg-Pro-Pro Gly-Phe ([1-5]BK) (Fig. 3A) . This was due mainly to the action of kininase II, as demonstrated by inhibition of the pentapeptide formation by captopril alone by 99% and the combination with MGPA (100%) ( Table  2) . Des-8,9-13K was rapidly converted by plasma to the pentapeptide [1] [2] [3] [4] [5] BK (Fig. 3B) , and the degradation of des-8,9-BK was markedly (94%) inhibited by captopril (Table 3 ), indicating that the degradation of both pep tides was mostly attributable to the action of kininase II. The tripeptidyl peptidase activity of angiotensin converting enzyme, which was reported previously (18) , was confirmed. It was reported that des-9-BK was degraded to des-8,9-BK in human serum (19) , whereas others stated that [1] [2] [3] [4] [5] BK was formed without generat ing des-8,9-BK when des-9-BK was incubated with purified kininase II (18, 20) . The present experiment confirmed the results reported by Oshima et al. (20) and those by Inokuchi and Nagamatsu (18) . The fol lowing results indicate that the [1] [2] [3] [4] [5] BK formation from des-9-BK or des-8,9-BK in human plasma is not in duced solely by kininase II: 1) partial inhibition (55%) of the degradation of des-9-BK by MGPA, accompa nied with reduced formation of [1] [2] [3] [4] [5] BK (Table 2) ; 2) the formation of des-8,9-BK from des-9-BK in the presence of captopril (Table 2) ; and 3) partial inhibi tion (43%) of the formation of [1] [2] [3] [4] [5] BK from des-8,9 BK by MGPA (Table 3) . These results could be ex plained partly by the involvement of kininase I in this degradation, but the participation of other peptidases susceptible to MGPA in human plasma could not be excluded. The possibility that MGPA inhibits kininase II is low, because of the failure of inhibition of com mercially available kininase II by MGPA.
Incubation of human plasma with BK, des-9-BK and des-8,9-BK did not result in the detection of Arg-Pro Pro. Even after the incubation of human plasma with [1] [2] [3] [4] [5] BK as a substrate, Gly-Phe and Phe were de tected, but the peak of Arg-Pro-Pro was hardly detect able with the present method (Figs. 4A, 4B, and 5) . Furthermore, the addition of the inhibitors of kininase I (MGPA) or II (captopril) or the combination of the inhibitors induced only slight (15-24%), but not signif icant, inhibition of the degradation of [1] [2] [3] [4] [5] BK or the formation of the total amounts of Gly-Phe and Phe (data not shown), indicating that the degradation was carried out by proteases other than kininases I and II, so that plasma degraded Arg-Pro-Pro very rapidly to the individual amino acids.
The present results were not consistent with those reported by Sheikh and Kaplan (12) that [1] [2] [3] [4] [5] BK was degraded to Arg-Pro-Pro-Gly or the tripeptide Arg Pro-Pro, and the tripeptide is the final product of BK degradation and stable in human serum. As seen in the chromatograph (Fig. 4C, 4D , and 5), the peak of Arg Pro-Pro, was hardly detectable under the present in cubation conditions, so that even if Arg-Pro-Pro was formed, it was negligible in amount compared with other peptides and amino acids, although Gly-Phe and Phe were detected. In fact, in the previous paper (12), Arg-Pro-Pro could be detected only when the scale of the ordinate was made ten times as large as that for the other experiments. The speed of degradation of Arg-Pro-Pro in human plasma may exceed that of the formation from [1] [2] [3] [4] [5] BK, as indicated by the half-lives of Arg-Pro-Pro (45 min) and [1] [2] [3] [4] [5] BK (4.2 hr). Figure 6 shows the degradation pathway of BK by human plasma. The half-lives of BK, des-9-BK, des 8,9-BK, [1] [2] [3] [4] [5] BK and Arg-Pro-Pro were approximately 60 min, 90 min, 14 min, 4.2 hr and 46 min, respectively, under our conditions for the incubation with plasma. Thus, [1] [2] [3] [4] [5] BK is thought to be the most stable of the BK degradation products. In the pleural fluid of rat carrageenin-induced pleurisy, BK could not be de tected, but its detection was made possible after treat ment of the rats with captopril (10 mg/kg, i.p.) (6) . However, des-8,9-BK was detected without captopril. An enzyme immunoassay of [1] [2] [3] [4] [5] BK, which we have developed, enabled the pentapeptide [1] [2] [3] [4] [5] BK to be de tected in much larger amounts than des-8,9-BK in the pleural exudate of the same inflammation model (M. Majima et al., to be published).
From these results in the present experiments, we may conclude that [1] [2] [3] [4] [5] BK is the most stable, long lived metabolite among the degradation products of BK and can be used as a useful marker to verify the kinin release in pathological states. Summary for degradation pathway of bradykinin in human plasma.
